Lung cancer screening has received extensive attention for a number of years. As yet the goal of such a screening programme, a reduction in lung cancer mortality proven by a large randomised controlled trial, has not been achieved. Instead we are left with a number of unanswered questions and practical problems. In addition to the basic requirements for an effective screening programme, this review will identify the main pitfalls in lung cancer screening, with particular reference to multislice computed tomography. The specific difficulties relating to the identification of unimportant disease, the failure to identify important disease successfully, the consequences of investigating and treating identified disease and the financial costs will all be discussed.

Author

M Goodwin * and F V Gleeson

Contact Details

Corresponding address:
Churchill Hospital, OX37LJ
Oxford
UK

Reference

ICIS Cancer Imaging volume 4
DOI: 10.1102/1470-7330.2004.0001

Date Posted

3 February 2004

Print PDF

Size

61.94 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	1 second
64 Kb/s (ISDN):	7 seconds
33.3 Kb/s (Typical Modem):	14 seconds

Screen PDF

Size

262.37 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	4 seconds
64 Kb/s (ISDN):	32 seconds
33.3 Kb/s (Typical Modem):	1 minute 3 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.